---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009478"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:55:54.093846+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Erasca reports Q4/FY2022 net loss of $135.3M/$242.8M; licensed naporafenib from Novartis, raised $100M equity

## Summary
- Net loss Q4 2022 $135.3M (incl. $100M in-process R&D for naporafenib license); FY2022 net loss $242.8M ($1.99/share).
- Cash, cash equivalents & marketable securities $435.6M at Dec 31, 2022; expected runway into H2 2025.
- Completed $100M underwritten equity offering (15.4M shares at $6.50) in Dec 2022 concurrent with naporafenib license.
- Multiple data readouts planned in 2023 for ERAS-007, ERAS-601, ERAS-801; naporafenib Phase 1b (SEACRAFT-1) starts H2 2023.
- R&D expenses FY2022 $112.5M (up 52% YoY) driven by license payments and clinical progress.

## SEC filing metadata
- accession: 0000950170-23-009478
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/0000950170-23-009478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/eras-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009478
- JSON: https://secwatch.observer/filing/0000950170-23-009478.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009478.txt

## Key facts
- Earnings Releases
  Erasca, Inc. reported financial results for the fiscal year ended December 31, 2022.
  - Period: the fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/0000950170-23-009478-index.htm
- Earnings Releases
  Erasca, Inc. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/0000950170-23-009478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.